Jeremy Nighohossian is a senior fellow and economist at the Competitive Enterprise Institute, focusing on health care policy. His expertise is in healthcare antitrust and regulation including Certificate of Need regulations and competition and federal and state reimbursement policies. Jeremy writes on how government regulation and dominance of the healthcare sector stifle innovation, reduce quality, and raise costs.
Jeremy holds a Ph.D. in economics from Texas A&M University and a B.S. in Chemical Engineering from the University of Illinois. Before joining CEI, he worked at the Center for Healthcare Economics and Policy at FTI Consulting where he specialized in anti-trust and disputes in healthcare working on several projects with Compass Lexecon. While at FTI, Dr. Nighohossian built a policy analysis practice where he conducted analyses of state and national healthcare policies. Jeremy’s expertise has taken him around the world, testifying to the South Africa Competition Commission on hospital prices and how they relate to supply and he helped design a value-based payment system in the UK.
Authored by Jeremy Nighohossian
News
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
FDA succeeds in approving new flu vaccine: CEI comment
The FDA has approved a flu vaccine made with mRNA technology, the same technology used for Moderna’s COVID-19 vaccine, the company announced on…
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Op-Eds/Articles
Issues & Insights
American Prosperity At 250
Americans are poised to celebrate 250 years of independence on July 4, but they seem to be pessimistic about the nation. When asked to…
Washington Examiner
The government has no business in AI
People worry about the ways artificial intelligence will change jobs, education, creativity, and daily lives, according to polling. But…
The Modesto Bee
Commentary: How AI is already improving lives
Leading AI models are doubling their capabilities every four months, and the implications for accelerating scientific research, improving education, and transforming much of the…
Studies
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs,…
I, Pharmaceutical
The global pharmaceutical industry is complex. This is true not only in the number of countries involved but the range of products, the sets…
Citations
PCMA
No More Excuses After Pharma-Backed PBM Reform Becomes Law
PCMA cited CEI’s expert on prescription prices Going further, a renewed focus on the way Big Pharma games the patent system to…
Freedom Works Radio
Jeremy Nighohossian, Competitive Enterprise Institute “Trump Healthcare Plan a Mixed Bag”: Freedom Works Radio Show
Freedom Works Radio show interviews CEI’s expert on healthcare Listen to Freedom Works Radio…
NewsTalkSTL
NewsTalkSTL: Jeremy Nighohossian of Competitive Enterprise Institute 1-19-2026
Regulatory Comments
CEI Comments on 340B Payment Change
The Competitive Enterprise Institute (CEI) submits these comments in support of several of the provisions in the rule recently proposed by CMS. Founded in…
CEI Comments on Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
Comments of the Competitive Enterprise Institute Dear Dr. Oz, The Competitive Enterprise Institute (CEI) submits these comments in support of several provisions…
CEI Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model
Comments of the Competitive Enterprise Institute Dear Dr. Oz, The Competitive Enterprise Institute (CEI) submits these comments in opposition to the creation…
Podcast Episodes
Obamacare Problems with Jeremy Nighohossian
This week we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and resources for reporting government corruption at...